| Stock | Price | 52 Week Range | Marketcap | EPS | Dividend Yield | Chart (24H) | Sector | Employees | Last Updated |
|---|---|---|---|---|---|---|---|---|---|
 189981 KNSY | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | |||
 458485 MIL | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | |||
| $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago | ||||
 Amedisys Inc AMED | $91.89 | 3.01B | 1.31 | 0.00% | Healthcare | 19,000 | 2 days ago | ||
 225143 URS | $0.0000 | 0.0000 | 0.00 | 0.00% | 0 | 6 years ago |
Investors, listen up. Finding stocks that outperform the market based on solid financial metrics can feel like mining for gold. But today, we’ve struck it rich. We’re diving deep into five outstanding stocks riding high on earnings momentum, and these aren’t just any stocks—they’re top picks from Louis Navellier’s Portfolio Grader.
Editor's Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace
Kensey Nash (NASDAQ: KNSY)
Overview
Kensey Nash is a pioneering company specializing in the development, manufacturing, and processing of resorbable biomaterials products. These advanced materials are essential in the medical devices market, an industry showing no signs of slowing down.
Investment Appeal
What really draws us to Kensey Nash? It earns an “A” in Operating Margin Growth, confirming its ability to generate increasing revenue from its operations efficiently. Kensey’s impressive grading on Portfolio Grader, particularly in operating margin metrics, signifies highly efficient management processes and robust profit margins. Advanced biomaterials are crucial in medical technology, contributing significantly to their earnings potential.
Relevance
The company’s advanced biomaterials technology aligns perfectly with the burgeoning medical devices market. As the sector grows, Kensey Nash is poised to capture a considerable share, driving continued revenue growth. If you’re aiming for a stock built on a foundation of efficiency and innovation, Kensey Nash is your ticket.
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $343.67 |
| Potential Gain | 14.1% |
| Number of Ratings | 6 |
Summary of Analysts’ Outlook:
Analysts have a bullish outlook on Kinsale Capital Group, Inc., with a consensus rating of Overweight. The average price target suggests a potential gain of 14.1% from the current price. Most analysts believe the company’s strong financial performance, expanding margins, and growing premiums will drive future growth.
For more information, get Portfolio Grader’s complete analysis of KNSY stock
MFC Industrial (NYSE: MIL)
Overview
MFC Industrial is an established global player in the supply and distribution of essential commodities and materials. Its extensive network and broad range of products place it at the heart of global trade and commerce.
Investment Appeal
Receiving stellar “A”s in Earnings Growth, Cash Flow, and Operating Margin Growth, MFC Industrial’s financial health is nothing short of impressive. This trifecta of strong metrics signals robust operational success and financial stability. It means MIL’s business model is not only operationally strong but also exhibits substantial earnings resilience and cash flow generation.
Relevance
The global marketplace for commodities is vast and growing. MFC Industrial’s strategic positioning in this space offers immense upside potential. For those eyeing the industrial and resource sectors, MFC Industrial represents a solid, lucrative investment candidate.
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Buy |
| Average Price Target | ₹34.50 (INR) |
| Potential Gain | 24.1% |
| Number of Ratings | 13 |
Summary of Analysts’ Outlook:
Analysts have a bullish outlook on MFC Industrial, with a consensus “Buy” rating. The average price target of ₹34.50 suggests a potential gain of 24.1% from the current price. Most analysts believe that the company’s strong financial performance, improving operating margins, and growth initiatives will drive its stock price upward.
For more information, get Portfolio Grader’s complete analysis of MIL stock
Alon USA Energy (NYSE: ALJ)
Overview
Alon USA Energy operates as an independent refiner and marketer of petroleum products across various regions of the United States. It’s a key player in the energy sector, balancing supply with growing energy demands.
Investment Appeal
Alon earns top marks in Earnings Growth, Analyst Earnings Revisions, and Equity. These accolades illustrate not just past performance but potential future gains, making it a jewel within the energy market. Alon’s strategic geographical footprint enhances its efficiency and market penetration, ensuring sustained operational performance.
Relevance
Strategic geographic operations give Alon a significant competitive edge. Consistent earnings growth and positive analyst revisions are clear indicators of its robust market positioning. Alon USA Energy stands out as a strong choice in an industry characterized by its volatility.
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Hold |
| Average Price Target | $1.25 |
| Potential Gain | 25.0% |
| Number of Ratings | 2 |
Summary of Analysts’ Outlook:
The limited analyst coverage suggests a neutral outlook for Alon USA Energy, with a consensus rating of “Hold”. The average price target of $1.25 implies a potential gain of 25.0% from the current price. However, please note that the low number of ratings and the limited coverage may not provide a comprehensive view of the stock’s prospects.
For more information, get Portfolio Grader’s complete analysis of ALJ stock
Amedisys (NASDAQ: AMED)
Overview
Amedisys is a major player in home health care and hospice services, serving various communities across the United States. With an aging population, the demand for its services is on a steady rise.
Investment Appeal
Amedisys secures “A”s in Earnings Surprises and Cash Flow, showcasing its capability to manage finances adeptly and exceed market expectations regularly. Superior cash flow positions Amedisys to not only survive but thrive during financial downturns and health crises.
Relevance
The growth trajectory in home health care demand is hard to ignore. Amedisys’ strong financial performance and operational excellence place it at the forefront of this expanding industry. For investors focusing on the health care sector, Amedisys presents a compelling opportunity.
Analyst Ratings and Forecasts:
| Metric | Value |
|---|---|
| Consensus Rating | Overweight |
| Average Price Target | $244.50 |
| Potential Gain | 14.1% |
| Number of Ratings | 13 |
Summary of Analysts’ Outlook:
Analysts have a positive outlook on Amedisys Inc., with a consensus rating of Overweight. The average price target of $244.50 suggests a potential gain of 14.1% from the current price. Overall, analysts believe that the company’s strong financial performance, growth initiatives, and industry trends will drive its stock price higher.
For more information, get Portfolio Grader’s complete analysis of AMED stock
URS Corp. (NYSE: URS)
Overview
URS Corp. offers diversified engineering, construction, and technical services across numerous market segments including power, infrastructure, federal, industrial, and commercial sectors. Its broad service offering positions it as a key player in these critical areas.
Investment Appeal
URS shines with “A”s in Earnings Surprises and Cash Flow. Such high marks indicate a dependable record of exceeding earnings expectations and maintaining substantial cash flow, both crucial for a thriving business. URS’s diversified portfolio ensures reduced risk, and consistent performance across various sectors further solidifies its stability.
Relevance
The company’s involvement in significant infrastructure projects and its diversified service portfolio suggest strong growth potential. For those interested in the engineering and construction services sector, URS Corp. stands out as a stable and promising investment.
Analyst Ratings and Forecasts:
Unfortunately, URS Corp. is a defunct company that was acquired by AECOM in 2014. Therefore, no current analyst ratings or forecasts are available for URS.
However, if you’re interested in AECOM (ACM), the company that acquired URS, or similar companies in the industry, feel free to explore their financial evaluations and prospects based on the latest data.
For more information, get Portfolio Grader’s complete analysis of URS stock
These five stocks aren’t just names; they represent the future of multiple booming sectors. Backed by outstanding financial metrics and strong market positions, each of these companies presents a rich opportunity for growth. Use this information to seize the moment and make your move.
* * *
Is the World Saying Farewell to the iPhone?
The iPhone has been Apple’s #1 product for over a decade…
But it may not even exist as we know it by September 10.
* * *
